A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1/2
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Sites
1
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-02 | actual | When the study began enrolling |
| Primary completion | 2025-12-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-19 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced/Recurrent Ovarian Cancer
Intervention
- Drug: Saruparib
Primary outcome
what the primary-completion date above is the date OFNumber of participants with treatment-emergent adverse event (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation
measured From Day 1 to Survival Follow up (approximately 6 months)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed